"{\n    \"1. Randomized indomethacin trial for prevention of intraventricular hemorrhage in very low birth weight infants\": {\n        \"explanation\": \"This paper is the same as the source paper, so it directly depends on the source's hypothesis and findings.\",\n        \"relevance\": 2\n    },\n    \"2. Indomethacin therapy on the first day of life in infants with very low birth weight\": {\n        \"explanation\": \"The hypothesis in this paper is inspired by the source paper's focus on indomethacin and its effects on neonatal conditions. It explores a related aspect, specifically the timing of indomethacin administration.\",\n        \"relevance\": 1\n    },\n    \"3. Early intravenous indomethacin prolongs respiratory support in very low birth weight infants\": {\n        \"explanation\": \"The hypothesis partially depends on previous findings about indomethacin. It uses similar treatment parameters but investigates a different outcome (chronic pulmonary disease) related to neonatal care.\",\n        \"relevance\": 2\n    },\n    \"4. Prevention of symptomatic patent ductus arteriosus with a single dose of indomethacin\": {\n        \"explanation\": \"The paper focuses on the prevention of symptomatic PDA with indomethacin, which is related to previous studies on indomethacin's effects on PDA and hemorrhage. It builds on the understanding that indomethacin affects the ductus arteriosus.\",\n        \"relevance\": 2\n    },\n    \"5. Administration of indomethacin for the prevention of periventricular-intraventricular hemorrhage in high-risk neonates\": {\n        \"explanation\": \"The hypothesis is strongly related to the initial studies as it directly investigates the use of indomethacin for preventing intraventricular hemorrhage, a focal point of previous research.\",\n        \"relevance\": 2\n    },\n    \"6. Randomized low-dose indomethacin trial for prevention of intraventricular hemorrhage in very low birth weight neonates\": {\n        \"explanation\": \"This paper is heavily dependent on previous findings as it specifically investigates low-dose indomethacin for preventing intraventricular hemorrhage, directly building on earlier work.\",\n        \"relevance\": 2\n    },\n    \"7. Prophylactic indomethacin for prevention of intraventricular hemorrhage in premature infants\": {\n        \"explanation\": \"The study examines the prophylactic use of indomethacin, a direct continuation of prior research on its effects on intraventricular hemorrhage and PDA.\",\n        \"relevance\": 2\n    },\n    \"8. Indomethacin reduces the risks of severe intraventricular hemorrhage\": {\n        \"explanation\": \"The hypothesis and findings depend on previous research regarding indomethacin's role in reducing severe IVH, continuing the exploration of indomethacin's preventive effects.\",\n        \"relevance\": 2\n    },\n    \"9. [Indomethacin in the prevention of subependymal-intraventricular hemorrhage in preterm newborns with conventional mechanical ventilation]\": {\n        \"explanation\": \"This study builds on previous findings by evaluating indomethacin's efficacy in preventing IVH in a specific group of mechanically ventilated neonates.\",\n        \"relevance\": 2\n    },\n    \"10. Low-dose indomethacin therapy and extension of intraventricular hemorrhage: a multicenter randomized trial\": {\n        \"explanation\": \"The hypothesis depends on the previous understanding of indomethacin's role in hemorrhage prevention, focusing on preventing the extension of existing hemorrhages.\",\n        \"relevance\": 2\n    },\n    \"11. Prophylactic indomethacin therapy in the first twenty-four hours of life for the prevention of patent ductus arteriosus in preterm infants treated prophylactically with surfactant in the delivery room\": {\n        \"explanation\": \"The paper is inspired by and builds on past research on indomethacin for PDA prevention, integrating it with surfactant therapy.\",\n        \"relevance\": 2\n    },\n    \"12. Effects of early indomethacin administration on oxygenation and surfactant requirement in low birth weight infants\": {\n        \"explanation\": \"This study is inspired by previous findings on respiratory support and indomethacin, exploring its effects on oxygenation and surfactant needs.\",\n        \"relevance\": 1\n    },\n    \"13. Indomethacin prophylaxis for patent ductus arteriosus (PDA) in infants with a birth weight of less than 1250 grams\": {\n        \"explanation\": \"The study builds on previous work on indomethacin for PDA prevention, with a focus on distinct birth weight categories.\",\n        \"relevance\": 2\n    },\n    \"14. Long-term effects of indomethacin prophylaxis in extremely-low-birth-weight infants\": {\n        \"explanation\": \"The hypothesis extends previous research by examining the long-term effects of indomethacin prophylaxis beyond immediate neonatal outcomes.\",\n        \"relevance\": 2\n    }\n}"
